MAPK8 and cancer: Treatment of ROR2-overexpressing cells with soluble WNT ligand antagonists such as sFRP1 or DKK1 as well as an inhibitor blocking non-canonical WNT-JNK signaling inhibited ROR2-induced cancer cell invasiveness (Fig. 4a).